Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Scanning mutagenesis of alpha-conotoxin Vc1.1 reveals residues crucial for activity at the alpha9alpha10 nicotinic acetylcholine receptor.
Halai R
,
Clark RJ
,
Nevin ST
,
Jensen JE
,
Adams DJ
,
Craik DJ
.
???displayArticle.abstract???
Vc1.1 is a disulfide-rich peptide inhibitor of nicotinic acetylcholine receptors that has stimulated considerable interest in these receptors as potential therapeutic targets for the treatment of neuropathic pain. Here we present an extensive series of mutational studies in which all residues except the conserved cysteines were mutated separately to Ala, Asp, or Lys. The effect on acetylcholine (ACh)-evoked membrane currents at the alpha9alpha10 nicotinic acetylcholine receptor (nAChR), which has been implicated as a target in the alleviation of neuropathic pain, was then observed. The analogs were characterized by NMR spectroscopy to determine the effects of mutations on structure. The structural fold was found to be preserved in all peptides except where Pro was substituted. Electrophysiological studies showed that the key residues for functional activity are Asp(5)-Arg(7) and Asp(11)-Ile(15), because changes at these positions resulted in the loss of activity at the alpha9alpha10 nAChR. Interestingly, the S4K and N9A analogs were more potent than Vc1.1 itself. A second generation of mutants was synthesized, namely N9G, N9I, N9L, S4R, and S4K+N9A, all of which were more potent than Vc1.1 at both the rat alpha9alpha10 and the human alpha9/rat alpha10 hybrid receptor, providing a mechanistic insight into the key residues involved in eliciting the biological function of Vc1.1. The most potent analogs were also tested at the alpha3beta2, alpha3beta4, and alpha7 nAChR subtypes to determine their selectivity. All mutants tested were most selective for the alpha9alpha10 nAChR. These findings provide valuable insight into the interaction of Vc1.1 with the alpha9alpha10 nAChR subtype and will help in the further development of analogs of Vc1.1 as analgesic drugs.
Armishaw,
Rational design of alpha-conotoxin analogues targeting alpha7 nicotinic acetylcholine receptors: improved antagonistic activity by incorporation of proline derivatives.
2009, Pubmed
Armishaw,
Rational design of alpha-conotoxin analogues targeting alpha7 nicotinic acetylcholine receptors: improved antagonistic activity by incorporation of proline derivatives.
2009,
Pubmed
Baker,
Pharmacological properties of alpha 9 alpha 10 nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras.
2004,
Pubmed
,
Xenbase
Callaghan,
Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation.
2008,
Pubmed
,
Xenbase
Cascio,
Structure and function of the glycine receptor and related nicotinicoid receptors.
2004,
Pubmed
Clark,
The synthesis, structural characterization, and receptor specificity of the alpha-conotoxin Vc1.1.
2006,
Pubmed
,
Xenbase
Clark,
Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII.
2005,
Pubmed
,
Xenbase
Clark,
The three-dimensional structure of the analgesic alpha-conotoxin, RgIA.
2008,
Pubmed
Dutertre,
Beta2 subunit contribution to 4/7 alpha-conotoxin binding to the nicotinic acetylcholine receptor.
2005,
Pubmed
,
Xenbase
Dutton,
alpha-Conotoxins: nicotinic acetylcholine receptor antagonists as pharmacological tools and potential drug leads.
2001,
Pubmed
Elgoyhen,
alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells.
2001,
Pubmed
,
Xenbase
Elgoyhen,
Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells.
1994,
Pubmed
,
Xenbase
Ellison,
Alpha-RgIA: a novel conotoxin that specifically and potently blocks the alpha9alpha10 nAChR.
2006,
Pubmed
,
Xenbase
Ellison,
Alpha-RgIA, a novel conotoxin that blocks the alpha9alpha10 nAChR: structure and identification of key receptor-binding residues.
2008,
Pubmed
Gehrmann,
Structure determination of the three disulfide bond isomers of alpha-conotoxin GI: a model for the role of disulfide bonds in structural stability.
1998,
Pubmed
Gómez-Casati,
Biophysical and pharmacological characterization of nicotinic cholinergic receptors in rat cochlear inner hair cells.
2005,
Pubmed
Hogg,
Alpha-conotoxins PnIA and [A10L]PnIA stabilize different states of the alpha7-L247T nicotinic acetylcholine receptor.
2003,
Pubmed
,
Xenbase
Hu,
Crystal structure at 1.1 A resolution of alpha-conotoxin PnIB: comparison with alpha-conotoxins PnIA and GI.
1997,
Pubmed
Itier,
Neuronal nicotinic receptors: from protein structure to function.
2001,
Pubmed
Jakubowski,
Determining sequences and post-translational modifications of novel conotoxins in Conus victoriae using cDNA sequencing and mass spectrometry.
2004,
Pubmed
Lips,
Coexpression of alpha 9 and alpha 10 nicotinic acetylcholine receptors in rat dorsal root ganglion neurons.
2002,
Pubmed
Livett,
Drugs from the sea: conopeptides as potential therapeutics.
2004,
Pubmed
Livett,
Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor.
2006,
Pubmed
Lovelace,
Cyclic MrIA: a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter.
2006,
Pubmed
McIntosh,
Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes.
1999,
Pubmed
Miljanich,
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
2004,
Pubmed
Nevin,
Are alpha9alpha10 nicotinic acetylcholine receptors a pain target for alpha-conotoxins?
2007,
Pubmed
,
Xenbase
Nguyen,
Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity.
2000,
Pubmed
Olivera,
Peptide neurotoxins from fish-hunting cone snails.
1985,
Pubmed
Olivera,
Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applications.
2008,
Pubmed
Olivera,
E.E. Just Lecture, 1996. Conus venom peptides, receptor and ion channel targets, and drug design: 50 million years of neuropharmacology.
1997,
Pubmed
Olivera,
Diversity of Conus neuropeptides.
1990,
Pubmed
Olivera,
Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery.
2007,
Pubmed
Peng,
Characterization of the human nicotinic acetylcholine receptor subunit alpha (alpha) 9 (CHRNA9) and alpha (alpha) 10 (CHRNA10) in lymphocytes.
2004,
Pubmed
Plazas,
Stoichiometry of the alpha9alpha10 nicotinic cholinergic receptor.
2005,
Pubmed
,
Xenbase
Quiram,
Structural elements in alpha-conotoxin ImI essential for binding to neuronal alpha7 receptors.
1998,
Pubmed
Sandall,
A novel alpha-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo.
2003,
Pubmed
Satkunanathan,
Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones.
2005,
Pubmed
Sgard,
A novel human nicotinic receptor subunit, alpha10, that confers functionality to the alpha9-subunit.
2002,
Pubmed
,
Xenbase
Terlau,
Conus venoms: a rich source of novel ion channel-targeted peptides.
2004,
Pubmed
Vincler,
Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors.
2006,
Pubmed
Wishart,
1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects.
1995,
Pubmed
